sarepta therapeutics nasdaq

Order byBest matchMost fresh

Sarepta Shares Sink

Sarepta's Setback Deepens With Another Gene Therapy Fatality

In response to these safety concerns, the U.S Food and Drug Administration (FDA) has requested that the label include a black box warning for acute liver injury (ALI) and acute liver failure (ALF), a...

GEN - Genetic Engineering and Biotechnology News · 9h

StockWatch: Sarepta Shares Nosedive after LGMD Gene Therapy Patient Dies

InvestorsHub on MSN · 2d

Sarepta Shares Sink After Patient Death in Early-Stage Gene Therapy Trial

FDA asks Sarepta to stop shipping gene therapy

Digest more

· 1d · on MSN

Sarepta falls as report suggests FDA weighing a request to stop gene therapy shipments

Shares of Sarepta Therapeutics (NASDAQ:SRPT) continued to fall on Friday as Reuters reported that the U.S. FDA plans to request the company to voluntarily halt all shipments of its gene therapy, Elevidys,

· 1d

Sarepta Says It Won't Comply With FDA Request to Stop Shipping Gene Therapy Elevidys

· 1d

Sarepta tells FDA it won’t halt shipments despite patient deaths

· 2d

FDA to ask Sarepta to stop shipping Duchenne gene therapy

The Food and Drug Administration will ask Sarepta Therapeutics to halt all shipments of its marketed gene therapy for Duchenne muscular dystrophy, a source familiar with the matter confirmed to BioPh...

· 1d

Sarepta Therapeutics crisis is huge blow to Duchenne families, company

· 1d

Exclusive: US FDA to request Sarepta to stop all shipments of gene therapy Elevidys, source says

Sarepta Therapeutics Stock Is Surging After The Bell: What's Going On?

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares are soaring in Wednesday’s after-hours session after the company announced a strategic restructuring and cost-cutting measures. What To Know: After the market close on Wednesday,

Sarepta Therapeutics: What's Happening With SRPT Stock?

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening financial situation.

3don MSN

Sarepta Therapeutics rises after restructuring, pipeline focus

Sarepta Therapeutics (NASDAQ:SRPT) saw its stock rise in after-hours trading following the announcement of a strategic review that will lead to a workforce reduction of approximately 500 employees, equating to a 36% decrease in staff.

Sarepta Therapeutics Provides Statement on ELEVIDYS

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement:

2don MSN

Sarepta (SRPT) Jumps Nearly 20% on Corporate Restructuring

Stocks on Sky High. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the top-performing companies on Thursday. Sarepta Therapeutics saw its share prices rise by 19.53 percent on Thursday to close at $21.